Estonia announces Q1, Q3 and Q4 DCP slots for drug submissions
This article was originally published in SRA
Estonian medicines regulator Ravimiamet has slots available for companies wishing to make marketing authorisation submissions via the EU decentralised procedure in the first, third and fourth quarters of 20121.
You may also be interested in...
Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.
The EU marketing application for cefiderocol that lost fast track status last July is now up for an opinion by the European Medicines Agency.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.